Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$5.67 USD

5.67
15,482,167

+1.80 (46.51%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $5.75 +0.08 (1.41%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

by Zacks Equity Research

Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

    Zacks Equity Research

    Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?

    by Zacks Equity Research

    IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.

      Zacks Equity Research

      Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

      by Zacks Equity Research

      Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

        Zacks Equity Research

        Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

        by Zacks Equity Research

        Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

          Zacks Equity Research

          Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?

          by Zacks Equity Research

          Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.

            Zacks Equity Research

            Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

            by Zacks Equity Research

            Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.

              Zacks Equity Research

              Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?

              by Zacks Equity Research

              Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.

                Zacks Equity Research

                Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?

                by Zacks Equity Research

                Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.

                  Zacks Equity Research

                  Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

                  by Zacks Equity Research

                  Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

                    Zacks Equity Research

                    Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

                    by Zacks Equity Research

                    Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

                      Zacks Equity Research

                      Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

                      by Zacks Equity Research

                      ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

                        Zacks Equity Research

                        Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod

                        by Zacks Equity Research

                        Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.

                          Zacks Equity Research

                          AstraZeneca's Lynparza Label Now Includes Breast Cancer

                          by Zacks Equity Research

                          AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

                            Zacks Equity Research

                            Teleflex (TFX), HealthTrust Rebond on Respiratory Products

                            by Zacks Equity Research

                            Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.

                              Zacks Equity Research

                              Walgreens Closes PharMerica Buyout as KKR's Minority Partner

                              by Zacks Equity Research

                              Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.

                                Zacks Equity Research

                                Myriad Genetics Presents Favorable EMBRACA Trial Results

                                by Zacks Equity Research

                                Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.

                                  Zacks Equity Research

                                  Myriad Genetics Rides on Solid Molecular Diagnostics Suite

                                  by Zacks Equity Research

                                  Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.

                                    Zacks Equity Research

                                    NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM

                                    by Zacks Equity Research

                                    NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.

                                      Zacks Equity Research

                                      Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory

                                      by Zacks Equity Research

                                      Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.

                                        Zacks Equity Research

                                        Here's Why You Should Invest in Cooper Companies (COO) Now

                                        by Zacks Equity Research

                                        Cooper Companies (COO) is consistently trying to boost inorganic growth.

                                          Zacks Equity Research

                                          Genomic Health (GHDX) Oncotype DX Score Test Data Positive

                                          by Zacks Equity Research

                                          Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.

                                            Zacks Equity Research

                                            Boston Scientific Receives FDA Nod for Vercise DBS System

                                            by Zacks Equity Research

                                            Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.

                                              Zacks Equity Research

                                              Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm

                                              by Zacks Equity Research

                                              Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.

                                                Zacks Equity Research

                                                Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife

                                                by Zacks Equity Research

                                                Hill-Rom's (HRC) upbeat long-term view buoys optimism.

                                                  Zacks Equity Research

                                                  Inogen Rides on Solid Product Portfolio Amid Forex Woes

                                                  by Zacks Equity Research

                                                  Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.